Head-To-Head Analysis: Milestone Pharmaceuticals (NASDAQ:MIST) & Bristol Myers Squibb (NYSE:BMY)

Bristol Myers Squibb (NYSE:BMY) and Milestone Pharmaceuticals (NASDAQ:MIST) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Bristol Myers Squibb and Milestone Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1	16	11	2	2.47
Milestone Pharmaceuticals	1	1	4	1	2.71

Bristol Myers Squibb presently has a consensus target price of $64.88, indicating a potential upside of 9.34%. Milestone Pharmaceuticals has a consensus target price of $6.40, indicating a potential upside of 712.29%. Given Milestone Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Bristol Myers Squibb.

Profitability

This table compares Bristol Myers Squibb and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%

Institutional & Insider Ownership

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by company insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Bristol Myers Squibb and Milestone Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19 billion	2.52	$7.05 billion	$4.54	13.07
Milestone Pharmaceuticals	$1.55 million	63.29	-$63.06 million	($0.69)	-1.14

Bristol Myers Squibb has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Bristol Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Bristol Myers Squibb has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.

Summary

Bristol Myers Squibb beats Milestone Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.